Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

37.77 -1.14 (-2.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease. 
Via Benzinga
Exposures Product Safety
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track. 
Via The Motley Fool
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
From Genentech
Via Business Wire
Why Roche Holdings Stock Withered on Wednesday
The company had a dispiriting update to offer about an investigational drug. 
Via The Motley Fool
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
The company reported a surprise profit in the second quarter, vs. expectations for losses. 
Via Investor's Business Daily
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
Via The Motley Fool
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... 
Via Benzinga
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... 
Via Benzinga
Exposures Product Safety
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
There are a number of pharmaceutical companies looking to make waves in the weight loss market. 
Via The Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased... 
Via Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with start-up investments. Flatiron's data aids Roche's oncology R&D despite... 
Via Benzinga
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Roche's latest breakthrough could be a game changer, but it's still too early to say. 
Via The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
This company hasn't made its debut on the weight-loss market yet, but it may. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.